# Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis

> **NCT03346369** · PHASE3 · UNKNOWN · sponsor: **Universitair Ziekenhuis Brussel** · enrollment: 35 (estimated)

## Conditions studied

- Secondary Hyperoxaluria
- Nephrolithiasis

## Interventions

- **DRUG:** Lanthanum Carbonate

## Key facts

- **NCT ID:** NCT03346369
- **Lead sponsor:** Universitair Ziekenhuis Brussel
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08-18
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2021-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03346369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03346369, "Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03346369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*